1. Home
  2. PSTV vs BMRA Comparison

PSTV vs BMRA Comparison

Compare PSTV & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PSTV
  • BMRA
  • Stock Information
  • Founded
  • PSTV 1996
  • BMRA 1971
  • Country
  • PSTV United States
  • BMRA United States
  • Employees
  • PSTV N/A
  • BMRA N/A
  • Industry
  • PSTV Medical/Dental Instruments
  • BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • PSTV Health Care
  • BMRA Health Care
  • Exchange
  • PSTV Nasdaq
  • BMRA Nasdaq
  • Market Cap
  • PSTV 10.4M
  • BMRA 9.8M
  • IPO Year
  • PSTV N/A
  • BMRA N/A
  • Fundamental
  • Price
  • PSTV $1.82
  • BMRA $0.36
  • Analyst Decision
  • PSTV Strong Buy
  • BMRA
  • Analyst Count
  • PSTV 1
  • BMRA 0
  • Target Price
  • PSTV $8.00
  • BMRA N/A
  • AVG Volume (30 Days)
  • PSTV 41.6K
  • BMRA 97.5K
  • Earning Date
  • PSTV 08-12-2024
  • BMRA 08-23-2024
  • Dividend Yield
  • PSTV N/A
  • BMRA N/A
  • EPS Growth
  • PSTV N/A
  • BMRA N/A
  • EPS
  • PSTV N/A
  • BMRA N/A
  • Revenue
  • PSTV $6,084,000.00
  • BMRA $5,405,208.00
  • Revenue This Year
  • PSTV $5.21
  • BMRA N/A
  • Revenue Next Year
  • PSTV N/A
  • BMRA N/A
  • P/E Ratio
  • PSTV N/A
  • BMRA N/A
  • Revenue Growth
  • PSTV 733.42
  • BMRA N/A
  • 52 Week Low
  • PSTV $0.97
  • BMRA $0.28
  • 52 Week High
  • PSTV $3.21
  • BMRA $2.13
  • Technical
  • Relative Strength Index (RSI)
  • PSTV 51.37
  • BMRA 22.80
  • Support Level
  • PSTV $1.40
  • BMRA $0.28
  • Resistance Level
  • PSTV $1.59
  • BMRA $0.51
  • Average True Range (ATR)
  • PSTV 0.16
  • BMRA 0.05
  • MACD
  • PSTV 0.04
  • BMRA -0.00
  • Stochastic Oscillator
  • PSTV 78.15
  • BMRA 33.43

About PSTV PLUS THERAPEUTICS Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

About BMRA Biomerica Inc.

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.

Share on Social Networks: